Webinars
Webinar | 11:30 am - 12:15 pm ET | March 07, 2019
In this first episode, we discussed a recent report from Empirical Research Partners titled “Big Data for Fundamental Investing”, that explores a use case on the biotech sector.
Empirical Research Partners’ U.S. Portfolio Strategist Rochester Cahan and Peter Hafez, Chief Data Scientist at RavenPack, discussed on Empirical Research Partners’ white paper highlighted in our blog post about biotech investing .
They specifically addressed:
When : Thursday, March 7th, 2019 11:30 AM - 12:15 PM ET
Where Online Registration is closed
The webinar is free to attend.
Rochester Cahan, CFA
U.S. Portfolio Strategist
Empirical Research Partners
Mr. Cahan is the U.S. Portfolio Strategist at Empirical Research Partners LLC, having joined the firm in 2013 to focus on a broad spectrum of research topics ranging from bottom-up stock-selection to top-down macroeconomic analysis. Prior to joining the firm, Mr. Cahan was the head of U.S. Quantitative Strategy for Deutsche Bank in New York. He also held quantitatively-focused positions at Macquarie Bank and Citigroup
Peter Hafez
Chief Data Scientist
RavenPack
Peter is a pioneer in the field of applied news analytics, bringing alternative data to banks and hedge funds. He has more than 15 years of experience in quantitative finance with companies such as Standard & Poor's, Credit Suisse First Boston, and Saxo Bank.
Email events@ravenpack.com
Please use your business email. If you don't have one, please email us at info@ravenpack.com.
We will process your personal data with the purpose of managing your personal account on RavenPack and offering our services. You can exercise your rights of access, rectification, erasure, restriction of processing, data portability and objection by emailing us at privacy@ravenpack.com. For more information, you can check out our Privacy Policy.
Your request has been recorded and a team member will be in touch soon.
We consider incorporating sentiment signals from news, earnings call transcripts, and insider transactions to boost the risk-adjusted returns, and revive factor performance.
We find stronger, more predictable market reactions when the words of company executives agree with their actions.
We have gathered 12 insights from 2021 research that can be leveraged in 2022.